GlassScriptPhysician profile
Patrick C Staropoli
NPI 1780117929
$37,483.23
in general payments reported to CMS, 2019-2025
19 companies · $23K in 2025
The $23K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $71.43 · 2021: $880 · 2022: $1,274 · 2023: $3,936 · 2024: $7,028 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Food and Beverage: $4,592 · Travel and Lodging: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,222.00 |
| Food and Beverage | $4,591.76 |
| Travel and Lodging | $1,489.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $22,875.07 | 2022-2025 | Syfovre |
| Ocular Therapeutix, INC. | $3,737.23 | 2024 | Dextenza |
| Genentech USA, INC. | $3,035.08 | 2021-2025 | Vabysmo |
| Eyepoint US, INC. | $1,948.50 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $1,490.87 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $787.74 | 2020-2023 | Constellation |
| Regeneron Pharmaceuticals, INC. | $531.11 | 2023-2025 | Eylea, Eylea Hd |
| Astellas Pharma US INC | $501.25 | 2023-2025 | Izervay |
| Allergan, INC. | $476.79 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $474.77 | 2019 | |
| Alimera Sciences, INC. | $456.59 | 2022-2024 | Iluvien, Yutiq |
| Abbvie INC. | $262.52 | 2022-2025 | Ozurdex |
| Harrow Eye, LLC | $162.33 | 2024 | Iheezo |
| Genentech, INC. | $150.98 | 2022 | |
| Dutch Ophthalmic, USA | $136.79 | 2023-2024 | Tissueblue, Eva, Combined Machine |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $130.74 | 2023 | |
| Ani Pharmaceuticals, INC. | $130.00 | 2025 | Yutiq |
| Dompe US, INC. | $124.80 | 2021 | |
| Biogen, INC. | $70.07 | 2023-2024 | Byooviz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Staropoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.